By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Summit Therapeutics Inc. insiders have been one-way buyers this past year: four people put roughly $114.6 million into the stock and nobody sold in open-market trades.
The largest purchase came from Zanganeh Mahkam (CEO), about $50 million. Notably, at least one C-suite executive was among the buyers.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 3 of the last 7 full quarters. On the institutional side, 242 funds reported holding SMMT at the end of Q2 2026, and more funds bought than sold.
Are insiders buying or selling SMMT stock?
In the last 12 months Summit Therapeutics Inc. insiders made open-market purchases worth about $114.6 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in SMMT?
The most recent open-market insider trade in SMMT was filed on 2026-06-12.
How many institutions own SMMT?
242 investment managers reported holding SMMT in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded SMMT?
No congressional trades in SMMT were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).